Amphastar Pharmaceuticals (AMPH) Competitors $26.87 -0.54 (-1.97%) Closing price 04:00 PM EasternExtended Trading$26.86 -0.01 (-0.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AMPH vs. CRSP, TGTX, PTCT, MENS, ACLX, PCVX, KRYS, ARWR, ACAD, and ADMAShould you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), PTC Therapeutics (PTCT), Jyong Biotech (MENS), Arcellx (ACLX), Vaxcyte (PCVX), Krystal Biotech (KRYS), Arrowhead Pharmaceuticals (ARWR), ACADIA Pharmaceuticals (ACAD), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Amphastar Pharmaceuticals vs. Its Competitors CRISPR Therapeutics TG Therapeutics PTC Therapeutics Jyong Biotech Arcellx Vaxcyte Krystal Biotech Arrowhead Pharmaceuticals ACADIA Pharmaceuticals ADMA Biologics CRISPR Therapeutics (NASDAQ:CRSP) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings. Which has higher earnings and valuation, CRSP or AMPH? Amphastar Pharmaceuticals has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$37.31M148.82-$366.25M-$5.43-11.24Amphastar Pharmaceuticals$731.97M1.71$159.52M$2.6710.06 Do analysts prefer CRSP or AMPH? CRISPR Therapeutics presently has a consensus target price of $71.50, suggesting a potential upside of 17.12%. Amphastar Pharmaceuticals has a consensus target price of $31.60, suggesting a potential upside of 17.60%. Given Amphastar Pharmaceuticals' higher probable upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 1 Sell rating(s) 7 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.50Amphastar Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Does the media favor CRSP or AMPH? In the previous week, CRISPR Therapeutics had 12 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 17 mentions for CRISPR Therapeutics and 5 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.01 beat CRISPR Therapeutics' score of 0.44 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Amphastar Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CRSP or AMPH more profitable? Amphastar Pharmaceuticals has a net margin of 18.64% compared to CRISPR Therapeutics' net margin of -1,229.43%. Amphastar Pharmaceuticals' return on equity of 20.76% beat CRISPR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-1,229.43% -20.05% -17.09% Amphastar Pharmaceuticals 18.64%20.76%9.68% Do institutionals and insiders hold more shares of CRSP or AMPH? 69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, CRSP or AMPH? CRISPR Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. SummaryAmphastar Pharmaceuticals beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks. Get Amphastar Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMPH vs. The Competition Export to ExcelMetricAmphastar PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.25B$4.32B$5.74B$10.35BDividend YieldN/A1.30%5.53%4.58%P/E Ratio10.0610.9476.3526.43Price / Sales1.7115.81466.9091.03Price / Cash5.577.1637.4661.85Price / Book1.763.4613.186.39Net Income$159.52M-$134.23M$3.29B$271.22M7 Day Performance-0.41%4.80%2.50%2.78%1 Month Performance-11.90%2.26%4.59%7.35%1 Year Performance-43.30%40.41%73.81%29.74% Amphastar Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPHAmphastar Pharmaceuticals4.1852 of 5 stars$26.87-2.0%$31.60+17.6%-43.6%$1.25B$731.97M10.062,028Positive NewsCRSPCRISPR Therapeutics3.1896 of 5 stars$57.84+2.8%$71.60+23.8%+30.0%$5.12B$37.31M-10.65460Analyst ForecastTGTXTG Therapeutics4.3521 of 5 stars$31.75-1.3%$46.25+45.7%+53.0%$5.10B$454.07M85.81290PTCTPTC Therapeutics3.9012 of 5 stars$58.98-3.5%$69.00+17.0%+64.8%$4.85B$806.78M8.461,410Positive NewsMENSJyong BiotechN/A$51.82-15.7%N/AN/A$4.68BN/A0.0031Gap DownHigh Trading VolumeACLXArcellx2.2775 of 5 stars$75.20-1.3%$114.31+52.0%-7.9%$4.23B$107.94M-21.9980PCVXVaxcyte1.9537 of 5 stars$31.00-3.6%$106.25+242.7%-70.4%$4.18BN/A-7.54160KRYSKrystal Biotech4.9415 of 5 stars$155.71+8.4%$209.00+34.2%-8.4%$4.16B$359.21M31.65210Positive NewsHigh Trading VolumeARWRArrowhead Pharmaceuticals4.1377 of 5 stars$28.67-3.5%$43.14+50.5%+62.5%$4.11B$3.55M-22.40400ACADACADIA Pharmaceuticals4.3504 of 5 stars$24.67+4.5%$29.65+20.2%+44.9%$3.98B$957.80M18.55510Trending NewsAnalyst ForecastOptions VolumeGap DownTrading HaltedADMAADMA Biologics3.2744 of 5 stars$15.30-5.0%$27.67+80.8%-20.2%$3.84B$426.45M17.79530 Related Companies and Tools Related Companies CRSP Competitors TGTX Competitors PTCT Competitors MENS Competitors ACLX Competitors PCVX Competitors KRYS Competitors ARWR Competitors ACAD Competitors ADMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMPH) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMPH Stock Alerts